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The HIV-1 integrase (IN) is one of the virally encoded
enzymes essential for retroviral replication (Brown, 1998)
and has emerged as an attractive target for the development
of new anti-AIDS drugs. IN catalyses the integration of
retro-transcribed viral DNA into the host cell’s genome
through two coordinated reactions (Asante-Appiah et al.,
1997). In the first step, IN recognizes the viral DNA ends
and cuts the conserved terminal dinucleotide (5′-…CA-
GT-3′) in a reaction known as 3′-processing. This reaction
occurs in the cytoplasm within a large viral nucleoprotein
complex known as the preintegration complex. In the sec-
ond step, IN catalyses the strand transfer reaction (integra-
tion process). The 3′ OH terminal of the recessed viral
DNA (5′-…CA-OH–3′) attacks host DNA as a nucle-
ophile. The integration process is completed by cleavage of
the unpaired dinucleotides from the 5′-ends of the viral
DNA and repair of the gaps between the viral and target
DNA. Since no human counterpart of IN is known, there
is considerable interest in developing effective and selective
IN inhibitors (Pommier et al., 2000; Neamati, 2001; De
Clercq, 2000).
In recent years a systematic screening of natural and syn-
thetic products as potential IN inhibitors has been per-
formed using purified IN (Chen et al., 2002). Several
inhibitors have emerged (Neamati et al., 2000; Neamati,
2002) and two compounds, S-1360 (Shionogi & Co. Ltd.;
Yoshinaga T et al., In vitro activity of a new HIV-1 inte-
grase inhibitor in clinical development, presented at the 9th
Conference on Retroviruses and Opportunistic Infections,
Seattle, USA, 2002 ) and L-870810 (Merck and Co. Inc.;
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In a search for new HIV-1 integrase (IN) inhibitors,
we synthesized and evaluated the biological activ-
ity of 5,6-dihydroxyindole-2-carboxylic acid
(DHICA) and a series of its derivatives. These com-
pounds were designed as conformationally con-
strained analogues of the acrylate moiety of 
caffeic acid phenethyl ester (CAPE). DHICA, an
intermediate in the biosynthesis of melanins, was
prepared as a monomeric unit by a novel synthetic
route. In order to perform coherent SAR studies,
two series of DHICA amides were synthesized. First,
to validate the utility of a previously identified
three-point pharmacophore based on CAPE in
inhibitor design, we prepared a series of benzyl- or
phenylethylamine substituted derivatives lacking
and containing hydroxyl groups. Second, dimers
of DHICA containing various aminoalkylamine
linkers were also prepared with a goal to increase
potency. All compounds were tested against puri-
fied IN and the C65S mutant in enzyme-based
assays. They were also tested for cytotoxicity in an
ovarian carcinoma cell line and antiviral activity in
HIV-1-infected CEM cells. Seven compounds inhib-
ited catalytic activities of purified IN with IC50 val-
ues below 10 µM. Further computational docking
studies were performed to determine the title
compounds’ mode of interaction with the IN active
site. The residues K156, K159 and D64 were the
most important for potency against purified IN.
Keywords: 5,6-dihydroxyindole-2-carboxylic acid,
catechol derivatives, HIV-1 integrase inhibitors,
docking studies
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Pais et al., 2002), have shown convincing therapeutic
potential and are currently under clinical evaluations.
A common characteristic of many compounds active
against IN is the presence of multiple aromatic rings with
polyaryl hydroxylation, frequently of the catechol type
(Fesen et al., 1994; LaFemina et al., 1995; Robinson et al.,
1996; Pommier et al., 1997). Indeed, based on SAR and
other studies (Farnet et al., 1998; Burke et al., 1995; Zhao
et al., 1997), the catechol moiety has been postulated to be
the pharmacophore of polyhydroxylated inhibitors. Their
likely site of action has been located in the catalytic core
domain of IN, as suggested by their activity on the enzyme
of deletion mutants (aminoacids 50–212) and dependence
on divalent cations (Hazuda et al., 1997).
Caffeic acid phenethyl ester (CAPE) was one of the first
reported natural product inhibitor of IN (Fesen et al., 1993,
1994). Several follow-up studies demonstrated the impor-
tance of the catechol moiety for activity (Burke et al., 1995;
Zhao et al., 1997). It was also shown that a majority of
reported IN inhibitors contain a three-point pharma-
cophore feature present in CAPE structure (Nicklaus et al.,
1997; Figure 1). In an attempt to identify new IN
inhibitors of natural origin, we fixed CAPE’s acrylate moi-
ety (I) (Fesen et al., 1993) in a constrained form by incor-
porating its vinyl bond into an indole ring, thereby obtain-
ing the 5,6-dihydroxyindole-2-carboxylic acid (DHICA
II) (Figure 2).
Interestingly, II has been recognized as the key
monomer intermediate in the biosynthesis of melanins,
the primary pigments of skin, hair and eyes in mammals
(Nicolaus, 1968; Nicolaus et al., 1964; Prota, 1992;
D’Ischia et al., 1996; Tsukamoto et al., 1992). Moreover,
this diffusible melanin precursor is a potent stimulator of
lipopolysaccharide-induced production of nitric oxide.
Furthermore, it has been hypothesized to play a role as a
chemical messenger mediating interaction between active
melanocytes and macrophages in epidermal inflammatory
and immune responses (D’Aquisto et al., 1995).
A novel synthetic route to II was performed followed
by the synthesis of a series of derivatives such as: i) amides
characterized by non-hydroxylated (IIIa and IIIb) or cat-
echol-containing (IIIc and IIId) aromatic groups; ii)
dimeric forms of II connected by linkers of various
lengths (IIIe-IIIi) (Figure 3). In this study we present the
inhibitory potency of the listed compounds against puri-
fied IN. Their cytotoxicity and antiviral activity were
studied in cell-based assays. Recently, we showed that
mercaptosalicylhydrazides designed to chelate Mg2+ on
the active site of IN also bind to C65. Therefore, some of
the most potent compounds presented in this study were
also evaluated in enzyme assays against the C56S mutant.
We also performed docking studies to investigate the
interactions between these compounds and the amino
acid residues on the IN active site.
Materials and methods
Chemistry
Anhydrous solvents and all reagents were purchased from
Aldrich, Merck or Carlo Erba. Anhydrous diethyl ether
was obtained by distillation from Na/benzophenone
under nitrogen. All reactions involving air- or moisture-
sensitive compounds were performed under nitrogen
using oven-dried glassware and syringes to transfer solu-
tions. Melting points (mp) were determined using an
Electrothermal melting point or a Köfler apparatus and
are uncorrected. Infrared (IR) spectra were recorded as
thin films or nujol mulls on NaCl plates with a Perkin-
Elmer 781 IR spectrophotometer and are expressed in ν
(cm-1). Nuclear magnetic resonance (1H-NMR and 13C-
NMR) spectra were determined in CDCl3, DMSO or
CDCl3/DMSO (in ratio 1:3) and were recorded on a
Varian XL-200 (200 MHz). Chemical shifts (δ scale) are
reported in parts per million (ppm) downfield from
tetramethylsilane (TMS) used as an internal standard.
Splitting patterns are designated as follows: s, singlet; d,
doublet; t, triplet; q, quadruplet; m, multiplet; brs, broad
singlet; dd, double doublet. The assignment of changeable
protons (OH and NH) was confirmed by the addition of
D2O. Analytical thin-layer chromatography (TLC) was
done on Merck silica gel F-254 plates. For flash chro-
matography, Merck Silica gel 60 was used with a particle
size 0.040–0.063 mm (230–400 mesh ASTM). Elemental
analyses were performed on a Perkin-Elmer 2400 spec-
trometer at Laboratorio di Microanalisi, Dipartimento di
Chimica, Università di Sassari (Italy), and were within
±0.4% of the theoretical values.
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Figure 1. Three-point pharmacophore used in the 3D
database searching based on CAPE structure 
(Nicklaus et al., 1997)
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Figure 3. DHICA derivatives
Preparation of azido-acetic acid methyl ester (2). A
solution of methyl bromoacetate (84.98 mmol) and sodium
azide (9.0 mmol) in DMF (21 mL) was stirred at room
temperature for 2.5 h. After the formation of a white solid,
an equivalent quantity of water was added and the resulting
solution was extracted three times with diethyl ether. The
organic layer was washed six times with water and dried
with sodium sulphate. The solvent was removed under
reduced pressure to obtain a yellow oil. Yield=94%; IR
(film) 2120 (N3), 1750 (C=O) cm
-1; 1H-NMR (CDCl3) δ
3.90 (s, 3H, OCH3), 3.81 (s, 2H, CH2).
General procedure for the preparation of 
azidocinnamates 3a and 3b. To a solution of the appropri-
ate aldehyde (1a and 1b) (1 mmol) and 2 (3.4 mmol) in
methanol (9 mL) a cold solution of sodium methoxyde 
(3 mmol) was added. The yellow slurry was stirred at –15°C for
4 h and then ice-cold water (36 mL) was added. The resulting
precipitate was filtered off and washed with water.
(E/Z)-2-Azido-3-benzo[1,3]dioxol-5-yl-acrylic acid
methyl-ester (3a). Yellow crystals. Yield=91%;
mp=61–62°C (from EtOH-H2O); IR (nujol) 2210 (N3),
1710 (C=O) cm-1; 1H-NMR (CDCl3) δ 7.57 (d, 1H, Ar-
H), 7.17 (dd, 1H, Ar-H), 6.83 (s, 1H, CH=C), 6.81 (d, 1H,
Ar-H) 6.00 (s, 2H, OCH2O), 3.89 (s, 3H, OCH3).
(E/Z)-2-Azido-3-(3,4-dimethoxyphenyl)-acrylic acid
methyl-ester (3b). Yellow crystals. Yield=58%;
mp=91–92°C (from EtOH-H2O); IR (nujol) 2120 (N3),
1700 (C=O) cm-1; 1H-NMR (CDCl3) δ 7.51 (d, 1H, Ar-
H), 7.35 (dd, 1H, Ar-H), 6.88 (s, 1H, CH=C), 6.87 (d, 1H,
Ar-H), 3.92 (s, 6H, OCH3 ×2), 3.90 (s, 3H, OCH3 ).
General procedures for the preparation of esters 4a
and 4b. A solution of the azidocinnamates 3a and 3b (4.04
mmol) in xylene (25 mL) was heated under reflux for 15
min. After cooling, the resulting pale yellow precipitate was
filtered and washed with petroleum ether.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid methyl-
ester (4a). Yellow crystals. Yield=79%; mp=194–195°C
(from EtOH-H2O); IR (nujol) 3319 (NH), 1690 (C=O)
cm-1; 1H-NMR (CDCl3) δ  9.10 (brs, 1H, NH), 7.09 (s,
1H, Ar-H), 6.96 (s, 1H, Ar-H), 6.83 (s, 1H, Ar-H), 5.96
(s, 2H, OCH2O), 3.91 (s, 3H, OCH3). Anal. Calcd for
C11H9NO4: C, 60.27; H, 4.14; N, 6.39. Found: C, 60.31;
H, 4.25; N, 6.19.
5,6-Dimethoxy-1H-indole-2-carboxylic acid methyl-
ester (4b). Yellow crystals. Yield=67%; mp=167–168°C
(from EtOH-H2O); IR (nujol) 3320 (NH), 1680 (C=O) cm
-
1; 1H-NMR (CDCl3) δ 9.12 (brs, 1H, NH), 7.12 (d, 1H,
Ar-H), 7.04 (s, 1H, Ar-H), 6.84 (s, 1H, Ar-H), 3.92 (s, 9H,
OCH3×3). Anal. Calcd for C12H13NO4: C, 61.27; H, 5.57;
N, 5.95. Found: C, 61.34; H, 5.70; N, 6.11.
General procedures for the preparation of acids 5a and
5b. A suspension of the esters 4a and 4b (2.28 mmol) in 17
mL of 12% KOH solution was heated under reflux for 1 h.
The clear solution was poured in ice-cold water and then
acidified with HCl 6N. The resulting white precipitate was
filtered and washed with water.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid (5a).
White crystals. Yield=98%; mp=248–250°C (dec.) (from
EtOH-H2O); IR (nujol) 3320 (NH), 1700 (C=O) cm
-1; 1H-
NMR (CDCl3:DMSO) δ 11.33 (brs, 1H, NH), 6.94 (s, 2H,
Ar-H), 6.88 (s, 1H, Ar-H), 5.93 (s, 2H, OCH2O), 4.08–2.75
(brs, 1H, COOH). Anal. Calcd for C10H7NO4: C, 58.54; H,
3.44; N, 6.83. Found: C, 58.60; H, 3.21; N, 6.97.
5,6-Dimethoxy-1H-indole-2-carboxylic acid (5b).
White crystals. Yield=98%; mp=210–212°C (dec.) (from
EtOH-H2O); IR (nujol) 3240 (NH), 1700 (C=O) cm
-1;
1H-NMR (CDCl3:DMSO) δ 9.90 (brs, 1H, NH), 7.11 (d,
1H, Ar-H), 7.04 (s, 1H, Ar-H), 6.91 (s, 1H, Ar-H),
4.65–3.82 (brs, 1H, COOH), 3.93, (s, 3H, OCH3) 3.91, (s,
3H, OCH3). Anal. Calcd for C11H11NO4: C, 59.73; H,
5.01; N, 6.33. Found: C, 59.55; H, 4.97; N, 6.45.
Preparation of 5,6-dihydroxy-1H-indole-2-carboxylic
acid (II). To a suspension of the acid 5a or 5b (1 mmol) in
dichloromethane (20 mL) at –40°C and under nitrogen
atmosphere, 1M BBr3 solution in dichloromethane (4
mmol) was added. The mixture was stirred, at the same
temperature, for 4 h. After the reaction was quenched with
water, the resulting precipitate was filtered, washed with
water and triturated with ether. The crude product was
purified by silica gel flash column chromatography (eluents
petroleum ether–ethyl acetate 3:7) and then recrystallized
two times with isopropylic alcohol. Yield: 21% (from 5a),
36% (from 5b); mp 235°C dec; IR (nujol) 3480 (COOH),
3430 (OH), 3300 (NH), 1700 (C=O) cm-1; 1H-NMR
(DMSO) δ 10.10 (brs, 1H, NH), 9.10 (brs, 1H, OH), 8.60
(brs, 1H, OH), 6.86 (s, 1H, Ar-H), 6.82 (s, 1H, Ar-H),
6.77 (s, 1H, Ar-H). 13C-NMR (DMSO) δ 162.8, 146.2,
142.1, 132.7, 125.9, 119.9, 107.2, 104.9, 97.1. Anal. Calcd.
for C9H7NO4: C, 55.96; H, 3.65; N, 7.25. Found: C, 55.77;
H, 3.69; N, 7.13.
General procedure for the preparation of the amides
8–16. A suspension of 5a (3.65 mmol) and PCl5 (5.48
mmol) in anhydrous diethyl ether (25 mL) was stirred at
room temperature for 2 h. The solvent was removed under
reduced pressure; the residue was washed twice with diethyl
M Sechi et al.
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ether and then washed three times with chloroform. The
acyl chloride obtained was dissolved in anhydrous diethyl
ether (25 mL) and a solution of the appropriate amine
(5.48 mmol) in 5 mL of dioxane was added dropwise. The
mixture was stirred at room temperature for 2 h and the
resulting precipitate was filtered and washed with water.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid benzyl-
amide (8). White powder. Yield=47%; mp=202–203°C; IR
(nujol) 3240 (NH), 1620 (C=O) cm-1; 1H-NMR
(CDCl3:DMSO) δ 10.81 (brs, 1H, NH), 8.07 (brs, 1H,
NH), 7.39–7.22 (m, 5H, Ar-H), 7.00 (s, 1H, Ar-H), 6.93
(s, 1H, Ar-H), 6.86 (s, 1H, Ar-H), 5.92 (s, 2H, OCH2O);
4.62 (d, 2H, NHCH2). Anal. Calcd for C17H14N2O3: C,
69.38; H, 4.79; N, 9.52. Found: C, 69.16; H, 4.61; N, 9.66.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid phenetyl-
amide (9). White powder. Yield=68%; mp=203–204°C; IR
(nujol) 3290 (NH), 1610 (C=O) cm-1; 1H-NMR
(CDCl3:DMSO) δ 10.47 (brs, 1H, NH), 8.90–8.30 (brs,
1H, NH), 7.45–7.20 (m, 5H, Ar-H), 6.94 (s, 1H, Ar-H),
6.91 (s, 1H, Ar-H), 6.83 (d, 1H, Ar-H); 5.93 (s, 2H,
OCH2O), 3.66 (q, 2H, NHCH2), 2.94 (t, 2H, CH2). Anal.
Calcd for C18H16N2O3.0.15H2O: C, 69.49; H, 5.29; N,
9.01. Found: C, 69.71; H, 4.98; N, 9.31.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid-(benzo-
[1,3]dioxol-5-yl-methyl)-amide (10). White powder.
Yield=66%; mp=210–211°C (dec.); IR (nujol) 3280 (NH),
1600 (C=O) cm-1; 1H-NMR (CDCl3:DMSO) δ 10.71
(brs, 1H, NH), 7.95 (brs, 1H, NH), 6.92–6.75 (m, 6H, Ar-
H), 5.92 (s, 4H,OCH2O ×2), 3.66 (d, 2H, NHCH2). Anal.
Calcd for C18H14N2O5.0.25H2O: C, 63.06; H, 4.26; N,
8.17. Found: C, 63.33; H, 4.35; N, 8.44.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid-[2-(3,4-
dimethoxy-phenyl)-ethyl]-amide (11). White powder.
Yield=64%; mp=201–202°C; IR (nujol) 3290 (NH), 1630
(C=O) cm-1; 1H-NMR (CDCl3:DMSO) δ 10.80 (brs, 1H,
NH), 7.56 (brs, 1H, NH), 6.94-6.91 (m, 3H, Ar-H),
6.80–6.75 (m, 3H, Ar-H), 5.92 (s, 2H, OCH2O), 3.84 (s,
3H, OCH3), 3.82 (s, 3H, OCH3), 3.63 (q, 2H, NHCH2),
2.88 (t, 2H, CH2). Anal. Calcd for C20H20N2O5.0.40H2O:
C, 63.96; H, 5.58; N, 7.46. Found: C, 63.88; H, 5.37; N,
7.65.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid-{3-[(5H-
[1,3]dioxolo[4,5-f]indole-6-carbonyl)-amino]-propyl}-
amide (12). Beige powder. Yield=42%; mp=268–269°C
(dec.); IR (nujol) 3280 (NH), 1630 (C=O) cm-1; 1H-NMR
(CDCl3:DMSO) δ 11.25 (brs, 2H, NH×2), 8.30 (brs, 2H,
NH×2), 6.97 (s, 2H, Ar-H), 6.93 (s, 2H, Ar-H); 6.91 (s,
2H, Ar-H×2), 5.93 (s, 4H, OCH2O×2), 4.72–3.72 (m, 4H,
NHCH2×2), 1.92–1.83 (m, 2H, CH2). Anal. Calcd for
C23H20N4O6: C, 61.60; H, 4.50; N, 12.49. Found: C, 61.83;
H, 4.31; N, 12.52.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid-{3-[(5H-
[1,3]dioxolo[4,5-f]indole-6-carbonyl)-amino]-butyl}-
amide (13). Beige powder. Yield=49%; mp=297–299°C
(dec.); IR (nujol) 3220 (NH), 1630 (C=O) cm-1; 1H-NMR
(CDCl3:DMSO) δ 11.20 (brs, 2H, NH×2), 8.16 (brs, 2H,
NH×2), 6.97 (s, 2H, Ar-H), 6.92 (s, 2H, Ar-H), 6.90 (s,
2H, Ar-H), 5.91 (s, 4H, OCH2O×2), 3.44–3.29 (m, 4H,
NHCH2×2), 1.80–1.52 (m, 4H, CH2×2). Anal. Calcd for
C24H22N4O6: C, 62.33; H, 4.79; N, 12.12. Found: C, 62.31;
H, 4.75; N, 12.34.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid-{3-[(5H-
[1,3]dioxolo[4,5-f]indole-6-carbonyl)-amino]-esyl}-
amide (14). Beige powder. Yield=39%; mp=252–254°C
(dec.); IR (nujol) 3320 (NH), 1620 (C=O) cm-1; 1H-NMR
(CDCl3:DMSO) δ 10.90 (brs, 2H, NH ×2), 7.80 (s, 2H,
NH×2), 6.94 (s, 2H, Ar-H), 6.91 (s, 2H, Ar-H), 6.89 (s,
2H, Ar-H), 5.92 (s, 4H, OCH2O×2), 3.42-3.30 (m, 4H,
NHCH2 ×2), 1.75–1.55 (m, 4H, CH2 ×2), 1.51–1.25 (m,
4H, CH2 ×2). Anal. Calcd for C26H26N4O6.0.25H2O: C,
63.09; H, 5.40; N, 11.32. Found: C, 63.33; H, 5.21; N,
11.40.
{4-[(5H-[1,3]Dioxolo[4,5-f]indole-6-carbonyl)-piper-
azin-1-y l } - {5H-[1,3]dioxolo[4,5-f ] indol-6-y l } -
methanone (15). White powder. Yield=37%;
mp=309–310°C; IR (nujol) 3290 (NH), 1580 (C=O) cm-1;
1H-NMR (CDCl3:DMSO) δ 11.39 (brs, 2H, NH ×2), 6.97
(s, 2H, Ar-H), 6.90 (s, 2H, Ar-H), 6.73 (s, 2H, Ar-H), 5.95
(s, 4H, OCH2O ×2), 3.92 (brs, 8H, NCH2 ×4). Anal. Calcd
for C24H20N4O6: C, 62.60; H, 4.38; N, 12.17. Found: C,
62.67; H, 4.52; N, 11.91.
5H-[1,3]Dioxolo[4,5-f]indole-6-carboxylic acid-[3-(4-
{2-[(5H-[1,3]dioxolo[4,5-f]indole-6-carbonyl)-amino]-
propyl}-piperazin-1-yl)-propyl]-amide (16). 
White powder. Yield=39%; mp=234–235=°C (dec.); IR
(nujol) 3200 (NH), 1630 (C=O) cm-1; 1H-NMR
(CDCl3:DMSO) δ 11.25 (brs, 1H, NH×2), 8.28 (brs, 2H,
NH×2), 6.97 (s, 2H, Ar-H), 6.94 (s, 2H, Ar-H), 6.88 (s,
2H, Ar-H), 5.94 (s, 4H, OCH2O×2), 4.05–3.22 (m, 12H,
CH2×2), 2.64–2.09 (m, 4H, CH2×2), 1.81–1.59 (m, 4H,
CH2×2). Anal. Calcd for C30H34N6O6: C, 62.71; H, 5.96;
N, 14.63. Found: C, 62.55; H, 6.07; N, 14.84.
General procedure for the preparation of 
catechols IIIa–IIIh. To a solution of the amides 8–15 (1
mmol) in dichloromethane (70 mL for 8, 100 mL for 9–11,
15 and 200 mL for 12–14) at –40°C and under nitrogen
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atmosphere, 1M BBr3 solution in dichloromethane (4
mmol for 8–11 and 8 mmol for 12–15) was added. The
mixture was stirred under nitrogen atmosphere at the indi-
cated temperature (–40°C for the amides 8–11 and 0°C for
12–14) for 4 h. The reaction was quenched with methanol,
washed three times with methanol and the solvents were
removed under reduced pressure. The crude product was
purified following method A) or B), depending on the
amides. Method A) consisted of silica gel flash column
chromatography (eluent petroleum ether–ethyl acetate 4:6
for IIIa and IIIb or ethyl acetate for IIIc and IIId or chlo-
roform–methanol 7:3 for IIIg) and trituration of the solid
with diethyl ether-petroleum ether to provide a powder
that was filtered off and collected. Method B) consisted of
washing with water and trituration of the solid with diethyl
ether for IIIe, IIIf and IIIh.
5,6-Dihydroxy-1H-indole-2-carboxylic acid-benzyl-amide
(IIIa). White powder. Yield=42%; mp=219–221°C; IR
(nujol) 3380 (OH), 3280 (NH), 1630 (C=O) cm-1;
1H-NMR (CDCl3:DMSO) δ 10.05 (brs, 1H, NH ), 8.02
(brs, 1H, OH), 7.86–7.69 (m, 2H, OH and NH),
7.42–7.19 (m, 5H, Ar-H), 7.00 (s, 1H, Ar-H), 6.90 (s, 2H,
Ar-H), 4.60 (d, 2H, NHCH2). Anal. Calcd for
C6H14N2O3: C, 68.07; H, 5.00; N, 9.92. Found: C, 68.21;
H, 5.09; N, 9.77.
5,6-Dihydroxy-1H-indole-2-carboxylic acid-phenetyl-
amide (IIIb). White powder. Yield=14%; mp=174–176°C;
IR (nujol) δ 3240 (OH), 3300 (NH), 1620 (C=O) cm-1;
1H-NMR (CDCl3:DMSO) δ 9.45 (brs, 1H, NH), 7.79
(brs, 1H, OH), 7.47 (brs, 1H, OH), 7.42–7.15 (m, 6H,
Ar-H and NH), 7.02 (s,1H, Ar-H), 6.91 (s, 1H, Ar-H),
6.66 (s, 1H, Ar-H), 3.68 (q, 2H, NHCH2), 2.93 (t, 2H,
CH2). Anal. Calcd for C17H16N2O3: C, 68.91; H, 5.44; N,
9.45. Found: C, 69.05; H, 5.57; N, 9.30.
5,6-Dihydroxy-1H-indole-2-carboxylic acid-(3,4-dihy-
droxy-benzyl-)-amide (IIIc). Grey powder. Yield=15%;
mp=265–267°C (dec.); IR (nujol) 3400 (OH), 3320 (NH),
1630 (C=O) cm-1. 1H-NMR (CDCl3:DMSO) δ 10.76
(brs, 1H, NH), 8.74 (brs, 2H, OH×2), 8.31 (brs, 2H,
OH×2), 7.60 (brs, 1H, NH), 6.98–6.71 (m, 4H, Ar-H),
6.70–6.52 (m, 2H, Ar-H), 4.32–4.05 (m, 2H, NHCH2).
Anal. Calcd for C16H14N2O5: C, 61.14; H, 4.49; N, 8.91.
Found: C, 61.22; H, 4.44; N, 8.99.
5,6-Dihydroxy-1H-indole-2-carboxylic acid-(3,4-dihy-
droxy-phenyl-ethyl)-amide (IIId). White powder.
Yield=47%; mp=221–223°C (dec.); IR (nujol) 3280
(NH), 3320 (OH), 1620 (C=O) cm-1; 1H-NMR
(CDCl3:DMSO) δ 10.59 (brs, 1H, N), 8.48 (brs, 4H,
OH×4), 7.92 (brs, 1H, NH), 6.91–6.62 (m, 5H, Ar-H),
6.50 (d, 1H, Ar-H), 3.60–3.42 (m, 2H, NHCH2), 2.71 (t,
2H, CH2). Anal. Calcd for C17H16N2O5: C, 62.19; H, 4.91;
N, 8.53. Found: C, 61.97; H, 5.04; N, 8.66.
5,6-Dihydroxy-1H-indole-2-carboxylic acid-{3-[(5,6-
dihydroxy-1H-indole-2-carbonyl)-amino]-propyl}-
amide (IIIe). Grey powder. Yield=29%; mp=208–210°C
(dec.); IR (nujol) 3380 (OH), 3280 (NH), 1630 (C=O) 
cm-1; 1H-NMR (CDCl3:DMSO) δ 10.85 (brs, 2H,
NH×2), 8.28 (brs, 4H, OH×4), 7.92 (brs, 2H, NH×2), 6.89
(s, 4H, Ar-H), 6.86 (s, 2H, Ar-H), 3.62–3.34 (m, 4H,
CH2×2), 2.05–2.76 (m, 2H, CH2). Anal. Calcd for
C21H20N4O6.0.15H2O: C, 59.05; H, 4.79; N, 13.12. Found:
C, 59.26; H, 4.87; N, 13.11.
5,6-Dihydroxy-1H-indole-2-carboxylic acid-{3-[(5,6-
dihydroxy-1H-indole-2-carbonyl)-amino]-butyl}-amide
(IIIf). Grey powder. Yield=59%; mp=304–306°C (dec.); IR
(nujol) 3400 (OH), 3200 (NH), 1630 (C=O) cm-1; 1H-
NMR (CDCl3:DMSO) δ 10.71 (brs, 2H, NH×2),
8.80–8.00 (brs, 4H, OH×4), 8.04 (brs, 2H, NH×2), 6.90 (s,
2H, Ar-H), 6.86 (s, 4H, Ar-H), 3.48–3.23 (m, 4H,
NHCH2×2), 1.80–1.55 (m, 4H, CH2×2). Anal. Calcd for
C22H22N4O6: C, 60.27; H, 5.06; N, 12.78. Found: C, 60.38;
H, 4.89; N, 12.82.
5,6-Dihydroxy-1H-indole-2-carboxylic acid-{3-[(5,6-
dihydroxy-1H-indole-2-carbonyl)-amino]-esyl}-amide
(IIIg). Red powder. Yield=26%; mp=201–204°C (dec.); IR
(nujol) 3300 (OH), 3200 (NH), 1610 (C=O) cm-1;
1H-NMR (CDCl3:DMSO) δ 10.75 (brs, 2H, NH×2),
8.10–7.98 (brs, 2H, OH×2), 7.90–7.65 (brs, 4H, OH×2
and NH×2), 6.86 (s, 2H, Ar-H), 6.83 (s, 4H, Ar-H),
3.43–3.22 (m, 4H, NHCH2×2), 1.75–1.55 (m, 4H,
CH2×2), 1.50–1.25 (m, 4H, CH2×2). Anal. Calcd for
C24H26N4O6.0.30H2O: C, 61.09; H, 5.68; N, 11.87. Found:
C, 61.28; H, 5.88; N, 12.08.
{4-[(5,6-Dihydroxy-1H-indole-2-carbonyl)-piperazin-1-
yl}-{5,6-dihydroxy-1H-indol-2-yl}-methanone (IIIh). 
Grey powder. Yield=55%; mp=242–244°C (dec.); IR
(nujol) 3380 (OH), 3280 (NH), 1640 (C=O) cm-1; 1H-
NMR (DMSO) δ 11.25 (brs, 2H, NH ×2), 9.23 (s, 2H,
OH), 8.76 (s, 2H, OH), 7.12 (s, 2H, Ar-H), 6.91 (s, 2H,
Ar-H), 4.13 (m, 8H, NCH2×4). Anal. Calcd for
C22H20N4O6: C, 65.55; H, 4.62; N, 12.84. Found: C, 65.71;
H, 4.45; N, 12.95.
Preparation of 5,6-dimethoxy-1H-indole-2-carboxylic
acid-pentafluorophenyl-ester (6). A solution of the acid
5b (9.94 mmol), pentafluorophenol (10.93 mmol) and
dicycloexylcarbodiimide (9.94 mmol) in 80 mL of dioxane
was stirred at room temperature for 4 h. After the suspen-
M Sechi et al.
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sion of dicycloexylurea was filtered off, the filtrate was evap-
orated under reduced pressure. The yellow residue obtained
was purified by silica gel flash column chromatography (elu-
ent, petroleum ether-ethyl acetate 8:2). Yield=88%;
mp=207–209°C; IR (nujol) 3340 (NH), 1700 (C=O) cm-1;
1H-NMR (CDCL3) δ9.22 (brs, 1H, NH), 7.43 (s, 1H, Ar-
H), 7.07 (s, 1H, Ar-H), 6.85 (s, 1H, Ar-H), 3.94 (s, 6H,
OCH3 ×2). Anal. Calcd for C17H10F5NO4: C, 52.73; H,
2.60; N, 3.62. Found: C, 52.81; H, 2.75; N, 3.68.
Preparation of 5,6-dihydroxy-1H-indole-2-carboxylic
acid-pentafluorophenyl ester (7). 1M BBr3 solution in
dichloromethane (3.7 mmol was added to a solution of 6
(1.23 mmol) in 20 mL dichloromethane at –40°C under
nitrogen atmosphere. The solution was stirred at the same
temperature for 4 h. After addition of water the resulting
precipitate was filtered and thoroughly washed with water.
Yield=32%; mp=220–221°C (dec.); IR (nujol) 3420 (OH),
3340 (NH), 1700 (C=O) cm-1; 1H-NMR (CDCl3:DMSO)
δ 10.68 (brs, 1H, NH), 8.23 (brs, 1H, OH), 8.01 (brs, 1H,
OH), 7.31 (d, 1H, Ar-H), 7.07 (s, 1H, Ar-H), 6.96 (s, 1H,
Ar-H). Anal. Calcd for C15H6F5NO4: C, 50.16; H, 1.68; N,
3.90. Found: C, 49.95; H, 1.73; N, 3.99.
Preparation of 5,6-Dihydroxy-1H-indole-2-carboxylic
acid-[3-(4-{2-[(5,6-dihydroxy-1H-indole-2-carbonyl)-
amino]-propyl}-piperazin-1-yl)-propyl]-amide (IIIi). 
A solution of 7 (0.83 mmol) and 1,4-bis-(3-aminopropyl)-
piperazine (0.27 mmol) in 5 mL of anhydrous DMF was
stirred, at 65°C under nitrogen atmosphere, for 16 h. After
addition of water the resulting precipitate was filtered,
washed with petroleum ether and triturated with diethyl
ether to obtain a grey powder. Yield=21%; mp=278–281°C
(dec.); IR (nujol) 3300 (OH), 1620 (C=O) cm-1; 1H-NMR
(CDCl3:DMSO) δ 11.02 (brs, 2H, NH), 6.92–6.81 (s, 4H,
Ar-H), 6.60 (s, 2H, Ar-H), 4.10–3.32 (m, 12H, CH2×6),
2.72–2.34 (m, 4H, NHCH2×2), 1.62–1.88 (m, 4H,
CH2×2). Anal. Calcd for C28H34N6O6: C, 61.08; H, 6.22;
N, 15.26. Found: C, 61.27; H, 6.26; N, 15.03.
Biology
Materials, chemicals and enzymes. All compounds were
dissolved in DMSO and the stock solutions were stored at
–20°C. The γ [32P]-ATP was purchased from either
Amersham Biosciences or ICN. The expression systems for
the wild-type IN and soluble mutant INF185KC280S were gen-
erous gifts of Dr Robert Craigie, Laboratory of Molecular
Biology, NIDDK, NIH, Bethesda, Md., USA. The expres-
sion system for the cysteine mutant enzymes was a gener-
ous gift of Dr Anna Marie Skalka, Fox Chase Cancer
Center, Philadelphia, Pa., USA and the proteins were pre-
pared as previously described (Yi et al., 1999; Asante-
Appiah et al., 1998).
Preparation of oligonucleotide substrates. The oligonu-
cleotides 21top, 5′-GTGTGGAAAATCTCTAGCAGT-
3′ and 21bot, 5′-ACTGCTAGAGATTTTCCACAC-3′
were purchased from Norris Cancer Center Core Facility
(University of Southern California) and purified by UV
shadowing on polyacrylamide gel. To analyse the extent of
3′-processing and strand transfer using 5′-end labelled sub-
strates, 21top was 5′-end labelled using T4 polynucleotide
kinase (Epicentre, Madison, Wis., USA) and γ [32P]-ATP
(Amersham Biosciences or ICN). The kinase was heat-
inactivated and 21bot was added in 1.5-molar excess. The
mixture was heated at 95°C, allowed slowly cool to room
temperature, and run through a spin 25 mini-column
(USA Scientific) to separate annealed double-stranded
oligonucleotide from unincorporated material.
Integrase assays. To determine the extent of 3′-processing
and strand transfer, wild-type IN was preincubated at a
final concentration of 200 nM with the inhibitor in reac-
tion buffer (50 mM NaCl, 1 mM HEPES, pH 7.5, 50 µM
EDTA, 50 µM dithiothreitol, 10% glycerol (w/v), 7.5 mM
MnCl2, 0.1 mg/ml bovine serum albumin, 10 mM 2-mer-
captoethanol, 10% dimethyl sulphoxide and 25 mM
MOPS, pH 7.2) at 30°C for 30 min. Then, 20 nM of the
5′-end 32P-labelled linear oligonucleotide substrate was
added, and incubation was continued for an additional 1 h.
Reactions were quenched by the addition of an equal vol-
ume (16 µl) of loading dye (98% deionized formamide, 10
mM EDTA, 0.025% xylene cyanol and 0.025% bromophe-
nol blue). An aliquot (5 µl) was electrophoresed on a dena-
turing 20% polyacrylamide gel (0.09 M tris-borate pH 8.3,
2 mM EDTA, 20% acrylamide, 8M urea).
Gels were dried, exposed in a PhosphorImager cassette,
analysed using a Typhoon 8610 Variable Mode Imager
(Amersham Biosciences) and quantitated using
ImageQuant 5.2. Percent inhibition (%I) was calculated
using the equation % I=100 X [1–D–C)/(N –C)], where C,
N and D are the fractions of 21-mer substrate converted to
19-mer (3′-processing product) or strand transfer products
for DNA alone, DNA plus IN and IN plus drug, respec-
tively. The IC50 values were determined by plotting the 
logarithm of drug concentration versus percent inhibition
to obtain concentration that produced 50% inhibition.
Cell culture and drug preparation
Human tumour-derived ovarian (HEY) cells were cultured
in RPMI 1640 media supplemented with 10% fetal bovine
serum (FBS) and 2 mM L-glutamine at 37°C in a humidi-
fied atmosphere of 5% CO2. Drugs were prepared in DMSO
at a concentration of 10 mM stock solution and stored at
–20°C. Further dilutions were freshly made in PBS.
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Table 1. Inhibition of HIV-1 integrase catalytic activities, cytotoxicity and antiviral activities of title 
compounds I, II, IIIa–i and intermediates 8–16
Cpds 3′-Processing Strand transfer CC50(µM) EC50(µM) CC50(µM)
IC50 (µM) IC50 (µM) CEM cells CEM cells HEY cells
Soluble mutant Soluble mutant C65S
I 5 5 10 – – –
II 6.5 ±1 6.0 ±1 – ND ND >20
IIIa 25 ±5 29 ±11 – 29 >29 >20
IIIb 3.5 ±0.2 2.6 ±0.4 – 24 >24 >20
IIIc 11 ±2 3 ±1 – 33 >33 >20
IIId 16 ±2 12 ±1 – 10 >10 >20
IIIe 4.2 ±1.2 4 ±2 6 3.6 >  3.6 >20
IIIf 3 ±1 2.3 ±1.3 4 26 >26 >20 
IIIg 46 ±6 18 ±1 – 26 >26 >20
IIIh 3.6 ±2.2 4.4 ±0.7 0.4 ND ND >20
IIIi 5 ±1 2.6 ±1.1 – 88 >88 >20 
8 >100 >100 – >200 >200 >20
9 >100 >100 – >200 >200 >20
10 >100 >100 – >200 >200 >20
11 >100 >100 – >200 >200 >20
12 >100 >100 – >200 >200 ND
13 >100 >100 – >200 >200 3 ±1
14 >100 >100 – >200 >200 0.1 ±0.01
15 >100 >100 – >200 >200 20 ±8
16 ND ND – ND ND ND
CC50 cytotoxic concentration 50%; EC50, effective concentration 50%; MTT, cytotoxicity assay using ovarian carcinoma cells; ND, not 
determined.
Table 2. Results of 50 independent runs for compounds II and IIIa–IIIi
Ligand *Ntot
†focc
‡∆Gbind H-bonds
II 27 5/5 –5.81 D64, C65, T66, K156, K159
IIIa 14 14/8 –5.26 D64, H67, N155, K159
IIIb 6 21/11 –5.42 D64, C65, K159
IIIc 12 22/10 –5.06 D64, T66, H67, Q148, N155, K159
IIId 6 28/9 –5.39 D64, T66, T115, F139, K156
IIIe 4 35/9 –6.74 C65, T66, P142, N144, Q148, N155
IIIf 6 40/5 –6.40 T66, P142, N144, K159
IIIg 2 48/2 –5.60 T66, N144, S147, N155
IIIh 13 19/9 –6.30 N155, K156, K159
IIIi 2 46/4 –6.09 D64, T66, H67, Q146, K159
*Total number of clusters. †Number of distinct conformational clusters found out of 50 runs/number of multi-member conformational 
clusters. ‡Estimated free binding energy (kcal/mol).
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Figure 4. Experimental conditions 
i) CH3ONa, CH3OH, –15°C for 4 h; ii) xylene, reflux for 15 min; iii) 12% KOH reflux for 1 h; iv) PCl5, Et2O, appropriate amine, rt; v) pentafluo-
rophenol, dioxane, r.t. for 4 h; vi) BBr3, CH2Cl2, H2O, –40°C for 4 h; vii) and viii) BBr3, CH2Cl2, CH3OH, –40°C for 4 h; ix) DMF, 1,4-bis(amino-
propyl)-piperazine, 65°C for 16 h.
Cell viability assay
The cytotoxicity of all drugs was assessed by MTT assay.
Briefly, ovarian cancer cells were seeded at a density of 
4000 cells/well in 96-well microtitre plates and allowed to
attach. Cells were subsequently treated with a continuous
exposure to the drugs for 72 h. An MTT solution (at a final
concentration of 0.5 mg/ml) was added to each well and cells
were incubated for 4 h at 37°C. After removal of the media,
DMSO was added and the absorbance was read at 570 nm.
Anti-HIV assays in cultured cell lines
The anti-HIV drug testing performed at the NCI was based
on a protocol described by Weislow et al. (1989). In brief, all
compounds were dissolved in DMSO and diluted in 1:100
in cell culture medium. Exponentially growing T4 lympho-
cytes (CEM cell line) were added at 5000 cells per well.
Frozen virus stock solutions were thawed immediately before
use, suspended in complete medium to yield the desired
multiplicity of infection (~0.1) and added to the microtitre
wells, resulting in a 1:200 final dilution of the compound.
Uninfected cells with the compound served as a toxicity con-
trol, and infected and uninfected cells without the compound
served as basic controls. Cultures were incubated at 37°C in
a 5% CO2 atmosphere for 6 days. The tetrazolium salt, XTT
[2,3-bis (2-methoxy-4-nitro-5-sulphenyl)-2H-tetrazolium-
5-carboxamide], was added to all wells and cultures were
incubated to allow formazan colour development by viable
cells. Individual wells were analysed spectrophotometrically
to quantitate formazan production, and in addition were
viewed microscopically for detection of viable cells and con-
firmation of protective activity.
Molecular modelling
Title compounds II and IIIa–IIIi were constructed with
standard bond lengths and angles from the fragment data-
base with MacroModel 6.0 (1997) using a Silicon Graphics
O2 workstation running IRIX 6.3. Sybyl 6.2 (2001) was
used as graphics platform. Compounds were modelled in
neutral form by standard molecular mechanics procedures,
with the single exception of DHICA (II). Because the car-
boxylic group of compound II has a pKa of ~5 under phys-
iological conditions, we used the deprotonated form for our
modelling studies. Docking calculations were performed on
HP Exemplar Parallel Server V2200 running HP UX 11.0.
The atomic charges were assigned using the Gasteiger-
Marsili procedure (Gasteiger et al., 1980). Minimization of
structures was performed with the MacroModel/BachMin
6.0 program using the AMBER force fields. Extensive
conformational search was carried out using the Monte
Carlo/Energy minimization (Chang et al., 1989) for all the
compounds considered in the study (Ei-Emin<5 Kcal/mol,
energy difference between the generated conformation and
the current minimum).
The subunit A of (PDB 1QS4) of the IN-5CITEP
complex was selected for all docking studies. The missing
residues at positions 141–144 in this subunit were incorpo-
rated from monomer B of the IN structure PDB 1BIS after
superimposition of the backbones of residues 135–140 and
145–150, as reported previously (Sotriffer et al., 2000).
Docking was performed with version 3.05 of the program
AutoDock (Morris et al., 1998), using the new empirical
free energy function and the Lamarckian protocol as
described (Morris et al., 1996).
Results 
Chemistry
The synthetic approach to compounds 5a and 5b and 8–16
used as starting material for the preparation of II,
IIIa–IIId and IIIe–IIIi is depicted in Figure 4. Starting
from the aldehydes 1a and 1b and methyl azidoacetate 2,
azidocinnamates 3a and 3b were prepared in high yield
according to the Hemetsberger reaction (Hemetsberger et
al., 1970; Knittel, 1985; Sechi et al., Design and synthesis
of novel indole β-diketo acid derivatives as HIV-1 inte-
grase inhibitors, under review). Intermediates 3a and 3b
were converted into the esters 4a and 4b in refluxing xylene
from which, on alkaline hydrolysis, the expected acids 5a
and 5b were obtained in 98% yields. Deprotection of the
catechol moiety with BBr3 in dichloromethane at –40°C
gave the expected DHICA II (Figure 4).
The intermediate 5a was treated with PCl5 and the acyl
chloride was then coupled with the appropriate amines to
give the amides 8–16. Deprotection of the catechol moi-
ety was carried out as described above to obtain the
desired compounds IIIa-IIIh. Since compound IIIi
could not be obtained by this route, we used the interme-
diate 5b that was converted into the pentaflurophenyl
ester 6. The latter was first deprotected into 7 and then
reacted with 1,4-bis(aminopropyl)-piperazine in DMF at
65°C to give IIIi in 21% yield.
Inhibition of HIV-1 IN catalytic activities 
Table 1 summarizes the in-vitro results of the title com-
pounds II, IIIa–IIIi and intermediates 8–16. Inhibition of
IN catalytic activities, 3′-processing and strand transfer
reactions were carried out using oligonucleotide-based
assays as described (Neamati et al., 2002). All target com-
pounds (II and IIIa–IIIi) showed anti-IN activity in
enzyme assays at low micromolar concentrations. In gener-
al, all the tested compounds showed equal potency against
both 3′-processing and strand-transfer activities of purified
IN. This fact prompted us to postulate that most of these
compounds are tightly bound to the pre-assembled IN-
DNA complex.
M Sechi et al.
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Figure 5. Graphical representation of hypothetical binding modes for monomers II, IIIb, IIIc and dimers IIIf, IIIi
WBR, west binding region; EBR, east binding region. Mg2+ ion is shown in magenta.
Discussion
II, IIIb, IIIc, IIIe, IIIf, IIIh and IIIi with IC50 values
ranging from 2–11 µM showed similar potency to that of
reference compound I (IC50=5 µM) (Zhang et al., 2001)
against purified IN.
The monomer II with IC50=6.5 ±1 µM and 6 ±1 µM
against 3′-processing and strand transfer activities, respec-
tively, proved to be one of the most potent compounds. The
high potency of DHICA (II) could be explained by its
unique arrangement in the IN active site, as detailed below.
The interaction of catechol with K159, as well as D64 with
indolic N-H and coordination with a Mg2+ cation in the IN
active site, could be responsible for high inhibitory potency
of compounds IIIb and IIIc. Substitution of the carboxyl
group of II with amide functionality led to compound IIIa,
which was about 5-fold less active. SAR studies suggested
that the anti-IN activity of IIIa could be slightly increased,
either by substitution of the aromatic hydrogen with a
cathecol system (compare IIIa and IIIc), or by elongation
of the alkylamide chain by one methylene unit (compare
IIIa and IIIb). A decrease in anti-IN potency was
observed when a cathecol system was added to IIIb to
obtain IIId. With the exception of IIIg, dimerization of II
to obtain compounds IIIe–IIIi did not lead to a significant
variation in activity. In the case of IIIe–IIIg, a rough cor-
relation between length of linker and activity could be
observed. In fact, the best activity was exhibited by com-
pound IIIf with IC50s=3 ±1 µM and 2.3 ±1.3 µM for 3′-
processing and strand transfer, respectively). Analogue IIIg
was significantly less potent. Also, IIIh and its correspond-
ing flexible analogue IIIi displayed potent inhibitory activ-
ities. On the other hand, the protected catechol intermedi-
ates 8–16 did not show significant activity at the highest
tested concentration (200 µM). This clearly indicates that
the free catechol functionality is necessary for a strong
interaction with the catalytic residues.
The above compounds potentially chelate divalent metal
ions. In addition it has been proposed that compounds,
such as mercaptosalicylhydrazides that chelate Mg2+ ions in
the active site of IN, bind to the C65 residue (Neamati
et al., 2002). Therefore we wanted to test the hypothesis
M Sechi et al.
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Table 3. Analysis of elements 
Theoretical Found
No. Formula C% H% N% C% H% N%
4a C11H9NO4 60.27 4.14 6.39 60.31 4.25 6.19
4b C12H13NO4 61.27 5.57 5.95 61.34 5.70 6.11
5a C10H7NO4 58.54 3.44 6.83 58.60 3.21 6.97
5b C11H11NO4 59.73 5.01 6.33 59.55 4.97 6.45
6 C17H10F5NO4 52.73 2.60 3.62 52.81 2.75 3.68
7 C15H6F5NO4 50.16 1.68 3.90 49.95 1.73 3.99
8 C17H14N2O3 69.38 4.79 9.52 69.16 4.61 9.66
9 C18H16N2O30.15H2O 69.49 5.29 9.01 69.71 4.98 9.31
10 C18H14N2O5.0.25H2O 63.06 4.26 8.17 63.33 4.35 8.44
11 C20H20N2O5.0.40H2O 63.96 5.58 7.46 63.88 5.37 7.65
12 C23H20N4O6 61.60 4.50 12.49 61.83 4.31 12.52
13 C24H22N4O6 62.33 4.79 12.12 62.31 4.75 12.34
14 C26H26N4O6.0.25H2O 63.09 5.40 11.32 63.33 5.21 11.40
15 C24H20N4O6 62.60 4.38 12.17 62.67 4.52 11.91
16 C30H34N6O6 62.71 5.96 14.63 62.55 6.07 14.84
II C9H7NO4 55.96 3.65 7.25 55.77 3.69 7.13
IIIa C16H14N2O3 68.07 5.00 9.92 68.21 5.09 9.77
IIIb C17H16N2O3 68.91 5.44 9.45 69.05 5.57 9.30
IIIc C16H14N2O5 61.14 4.49 8.91 61.22 4.44 8.99
IIId C17H16N2O5 62.19 4.91 8.53 61.97 5.04 8.66
IIIe C21H20N4O6.0.15H2O 59.05 4.79 13.12 59.26 4.87 13.11
IIIf C22H22N4O6 60.27 5.06 12.78 60.38 4.89 12.82
IIIg C24H26N4O6.0.30H2O 61.09 5.68 11.87 61.28 5.88 12.08
IIIh C22H20N4O6 65.55 4.62 12.84 65.71 4,45 12.95
IIIi C28H34N6O6 61.08 6.22 15.26 61.27 6.26 15.03
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that C65 binding is important for activity. The top-ranking
compounds IIIe, IIIf and IIIh were active against the
C65S (Yi et al., 1999) mutant, which implies that this
residue does not bind to these compounds. Interestingly,
while I was half as active against the C65S mutant as the
wild type IN (Zhang et al., 2001), IIIh showed 10 times
greater potency against the C65S mutant than the wild
type IN. In this case, the mutation of Cys to Ser could be
favourable for the inhibitory activity of IIIh. IIIe and IIIf
inhibited both enzymes with similar potency. It is also
noteworthy that IIIe, IIIf and IIIh were 1.6-, 2.5- and 25-
fold more active than I against C65S, respectively.
Molecular modelling
Previously, several computational docking studies using the
IN-5CITEP co-crystal structure (Goldgur et al., 1999)
were reported (Sotriffer et al., 2000; Polanski et al., 2002;
Ouali et al., 2000). We applied similar docking procedure
to investigate the interactions of II and IIIa–IIIi, with the
amino acid residues of the IN catalytic site. The results of
clusterized docking runs with the most favourable free
binding energy for each compound are given in Table 2.
Graphical representations of top-ranking binding modes
obtained for II, IIIb, IIIc, IIIf and IIIi showing the
important residues involved in binding are depicted in
Figure 5 and Table 3. According to docking results, the
amino acid residues involved in the binding of title com-
pounds located near the catalytic site were as follows: D64,
C65, T66, H67, T115, F139, P142, N144, Q146, S147,
Q148, N155, K156 and K159. Several of these were con-
sidered to be very important for the activity of IN (Neamati
et al., 2000) and to some have been previously shown to
play a role in substrate binding (Sotriffer et al., 2000). In
general, different ligands showed different binding modes
with some overlapping features, which were predicted as
potential H-bonds and van der Waals interactions.
In order to better analyse the docking results, the struc-
tures of title compounds were divided into two main groups
constituted by monomers II, IIIa–IIId and dimers
IIIe–IIIi. Compound II was found to bind to both K156
and K159, two sites important for DNA and mononu-
cleotide binding ( Jenkins et al., 1997; Esposito et al.,
1998; Drake et al., 1998). In addition, II also interacts
with T66 (through the indole NH), D64 and C65, both
residues located near the Mg2+ (through the indole cate-
chol group). On the other hand, the active monomeric
derivatives (IIIa–IIId) showed different orientation 
patterns and binding modes within the IN active site. In
fact, they form H-bonds with either K156 or K159
through the indole catechol (IIIa, IIIb and IIId) or the
phenyl (IIIc) moieties. Moreover, they were found to
share similar binding with D64 through their indole NH
(IIIb–IIId) or carboxamide group (IIIa), and with either
C65 (IIIb) or T66 (IIIc and IIId) through the catechol
groups of the indole (IIIb and IIId) or phenyl (IIIc)
moieties.
The plane of the indole of IIIa is rotated by approxi-
mately 180° with respect to that of IIIb and IIId, and
D64 interacts with the NH of the amide function rather
than with the indolic NH. This could be the reason for
the significantly lower anti-IN activity of IIIa with
respect to IIIb and IIId. However, the opposite disposi-
tion in the IIIc site did not influence the activity. This
observation can be consistent with the additional interac-
tion by the indolic catechol with Q148. This confirms
that the HIV-1 IN active site is quite large and relatively
shallow and therefore able to accommodate large varia-
tions in ligand size and shape with different binding
modes. The lower activity of the dimer IIIg may be
explained considering that this compound does not inter-
act with K156, K159 and D64, a recurrent motif 
important for activity.
Dimeric compounds IIIe–IIIi interact with additional
binding regions and significantly differ on their positions on
the IN active site. While half of the molecule occupies the
same space as monomers (the west binding region, as dis-
cussed by Buolamwini et al., 2002), the other half uses the
area in front of the two catalytic aspartates but without con-
tacting them (east binding region). With the exception of
IIIh, all dimers establish H-bonds with T66 through one of
the cathecol oxygens (interaction on the west region) while
the other oxygen interacts with either C65 (IIIe) or K159
(IIIf and IIIi). The indole catechol of IIIh instead H-bonds
with both K156 and K159. Moreover, indolic NH displayed
H-bonding with either N155 (IIIe and IIIh) or D64 (IIIi)
while the carboxamide group interacts with Q148 (IIIe) or
D64 (IIIi). On the east  binding region the other indole 
catechol portion establishes H-bonds with both P142 and
N144 (IIIe and IIIf) and with either N144 (IIIg) or Q146
(IIIi). Our docking results indicated that the estimated free
binding energy values and corresponding inhibition constant
(Ki) values were, in general, higher than the IC50 values
obtained experimentally.
Cytotoxicity and antiviral activity
Previously, it was shown that hydroxylated aromatics show
significant cytotoxicity and some can cross-link proteins
(Stanwell et al., 1996). It was recently shown that catechol-
containing compounds are potent inhibitors of lipoxygenase
and inhibit cell growth in low micromolar concentration
(Simpson et al., 2003). In our cancer screen, none of the tar-
get compounds showed significant activity against ovarian
carcinoma cells. Interestingly, some of the protected com-
pounds (13, 14 and 15) showed significant cytotoxicity.
Surprisingly 14 displayed high cytotoxicity against HEY
cells (CC50=0.1 ±0.01 µM) and studies are underway to
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determine its mechanism of cytotoxicity.
When we expanded our study to include cytoprotection
activity of the title compounds II and IIIa–i as well as 8–16
against HIV-1-infected CEM cells we observed that the target
compounds II and IIIa–IIIi were toxic and did not yield ther-
apeutic efficacy. These observations are consistent with previ-
ous studies (Burke et al., 1995; Neamati, 2002). We also
observed that none of the protected compounds 8–16 showed
antiviral activity at the highest tested concentration (200 µM).
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